Enanta Pharmaceuticals | ENTA - Current Assets


Enanta Pharmaceuticals reported $198.68M in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
AbbVie USD 29.06B 523M Dec/2025
Amgen USD 29.06B 1.17B Dec/2025
Anika Therapeutics USD 103.36M 1.77M Dec/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
AstraZeneca USD 28.72B 1.22B Dec/2025
BioCryst Pharmaceuticals USD 404.35M 48.66M Dec/2025
Biogen USD 8.97B 37.5M Dec/2025
Bristol-Myers Squibb USD 35.63B 2.41B Sep/2025
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 19.89B 1.05B Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Halozyme Therapeutics USD 825.21M 503.54M Dec/2025
Heron Therapeutics USD 238.07M 8.67M Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Incyte USD 5.02B 746.01M Dec/2025
Insmed USD 1.79B 137.6M Dec/2025
Ionis Pharmaceuticals USD 2.99B 471.01M Dec/2025
J&J USD 55.62B 1.01B Dec/2025
Karyopharm Therapeutics USD 89.75M 8.12M Sep/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Novartis USD 30.46B 2.26B Dec/2025
Novavax USD 978.28M 3.69M Dec/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.27B 266.14M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sarepta Therapeutics USD 2.54B 184.37M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025